Profile data is unavailable for this security.
About the company
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
- Revenue in USD (TTM)3.92m
- Net income in USD-38.37m
- Incorporated2018
- Employees45.00
- LocationHCW Biologics Inc2929 N Commerce Pkwy, Miramar, Fl 33025MIRAMAR 33025United StatesUSA
- Phone+1 (954) 842-2024
- Fax+1 (954) 842-2037
- Websitehttps://hcwbiologics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Palatin Technologies, Inc. | 5.90m | -32.20m | 20.65m | 34.00 | -- | 13.08 | -- | 3.50 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
Biora Therapeutics Inc | 860.00k | -86.81m | 21.41m | 58.00 | -- | -- | -- | 24.90 | -5.57 | -5.56 | 0.024 | -2.49 | 0.0253 | -- | 1.05 | 14,827.59 | -255.56 | -122.84 | -- | -369.01 | -- | -- | -10,094.19 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
Vincerx Pharma Inc | 0.00 | -28.90m | 21.67m | 42.00 | -- | 1.40 | -- | -- | -1.31 | -1.31 | 0.00 | 0.5206 | 0.00 | -- | -- | 0.00 | -101.76 | -- | -136.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
Pieris Pharmaceuticals Inc | 20.87m | -23.82m | 22.76m | 46.00 | -- | 1.22 | -- | 1.09 | -19.12 | -19.12 | 16.67 | 14.17 | 0.3707 | -- | 17.13 | 453,739.10 | -42.31 | -28.41 | -66.27 | -39.69 | -- | -- | -114.11 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
Hcw Biologics Inc | 3.92m | -38.37m | 23.19m | 45.00 | -- | -- | -- | 5.91 | -1.04 | -1.04 | 0.1068 | -0.1666 | 0.1183 | -- | 5.76 | 87,170.22 | -115.73 | -- | -199.07 | -- | 31.17 | -- | -978.10 | -- | -- | -146.50 | 2.75 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
Cognition Therapeutics Inc | 0.00 | -31.08m | 23.26m | 25.00 | -- | 1.01 | -- | -- | -0.9317 | -0.9317 | 0.00 | 0.5736 | 0.00 | -- | -- | 0.00 | -79.36 | -- | -104.49 | -- | -- | -- | -- | -- | -- | -263.29 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
Bolt Biotherapeutics Inc | 11.17m | -66.17m | 23.65m | 100.00 | -- | 0.2754 | -- | 2.12 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
Iterum Therapeutics PLC | 0.00 | -28.34m | 23.95m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
Unity Biotechnology Inc | 0.00 | -27.86m | 24.43m | 19.00 | -- | 1.24 | -- | -- | -1.80 | -1.80 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.05 | -47.21 | -45.11 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
Tron Pharmaceuticals Inc | 1.01m | -549.47k | 24.66m | 50.00 | -- | -- | -- | 24.42 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
Geovax Labs Inc | 300.68k | -26.92m | 24.74m | 17.00 | -- | -- | -- | 82.28 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Promis Neurosciences Inc | 0.00 | -12.20m | 24.76m | 6.00 | -- | -- | -- | -- | -0.6924 | -0.6924 | 0.00 | -0.1201 | 0.00 | -- | -- | 0.00 | -839.15 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | -- | -- | -- | -- | 26.85 | -- | -- | -- |
Neurosense Therapeutics Ltd | 0.00 | -11.88m | 25.31m | 16.00 | -- | -- | -- | -- | -0.7299 | -0.7299 | 0.00 | -0.4488 | 0.00 | -- | -- | 0.00 | -350.36 | -- | -5,244.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
Cue Biopharma Inc | 8.30m | -46.96m | 25.49m | 53.00 | -- | 1.18 | -- | 3.07 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Nuo Therapeutics Inc | 1.03m | -2.69m | 25.63m | -- | -- | 41.78 | -- | 24.92 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Lipocine Inc | 4.80m | -8.49m | 25.88m | 17.00 | -- | 1.22 | -- | 5.39 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Avantax Planning Partners, Inc.as of 30 Jun 2024 | 279.54k | 0.74% |
Hightower Advisors LLCas of 31 Mar 2024 | 179.81k | 0.48% |
Geode Capital Management LLCas of 30 Jun 2024 | 170.39k | 0.45% |
Cresset Asset Management LLCas of 31 Mar 2024 | 131.99k | 0.35% |
Pullen Investment Management LLCas of 30 Jun 2024 | 85.12k | 0.23% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 84.70k | 0.22% |
HRT Financial LLCas of 31 Mar 2024 | 73.11k | 0.19% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 42.65k | 0.11% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 37.65k | 0.10% |
AE Wealth Management LLCas of 31 Mar 2024 | 30.00k | 0.08% |